The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.

Abstract:

:Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacokinetic properties: it is metabolized by cytochrome P450 (CYP) 3A4 and flavin-containing monooxygenase 3 (FMO3), or excreted from the kidney in an unchanged form. Because of its multiple elimination pathways, dose adjustment is not needed in patients with hepatic or renal impairment, and it is considered to have a low potential for drug-drug interactions. Clinical studies and postmarketing surveillance show that teneligliptin, administered as monotherapy and/or in combination with antihyperglycemic agents, is effective and well tolerated in T2DM patients, including in elderly patients and those with renal impairment. Furthermore, teneligliptin has antioxidative properties, which induce the antioxidant cascade, as well as ·OH scavenging properties. In addition, it has shown endothelial protective effects in several non-clinical and clinical studies. From its unique profile and clinical data, teneligliptin represents a potential therapeutic option in a wide variety of patients, including elderly diabetic patients and those with renal impairment. The fixed-dose combination (FDC) tablet of teneligliptin and canagliflozin has been approved in Japan; this is the first FDC tablet of a DPP-4 inhibitor and sodium glucose co-transporter 2 inhibitor in Japan, and the third globally. The FDC tablet may also provide additional prescribing and adherence benefits.

journal_name

Drugs

journal_title

Drugs

authors

Ceriello A,De Nigris V,Iijima H,Matsui T,Gouda M

doi

10.1007/s40265-019-01086-0

subject

Has Abstract

pub_date

2019-05-01 00:00:00

pages

733-750

issue

7

eissn

0012-6667

issn

1179-1950

pii

10.1007/s40265-019-01086-0

journal_volume

79

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Treatment of gastroenteritis in children.

    abstract::Mortality and morbidity in gastroenteritis in children is the result of fluid loss, acid-base and electrolyte imbalance. Hence therapy should be aimed at preventing or correcting this imbalance. The use of intestinal antibiotics to treat the condition should not be a routine, but parenteral antibiotic therapy in the p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197611040-00004

    authors: Tan G

    更新日期:1976-01-01 00:00:00

  • Pharmacotherapy for oesophagogastric cancer.

    abstract::Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767170-00006

    authors: Jackson C,Starling N,Chua YJ,Cunningham D

    更新日期:2007-01-01 00:00:00

  • Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

    abstract::Recent developments in diagnosis and therapy of cytomegalovirus (CMV) infection have helped to reduce CMV-associated mortality following organ transplantation. However, CMV is still associated with significant morbidity in recipients of an allogeneic stem cell or solid-organ transplant. The clinical symptoms of active...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855010-00005

    authors: Hebart H,Kanz L,Jahn G,Einsele H

    更新日期:1998-01-01 00:00:00

  • Insulin glargine: an updated review of its use in the management of diabetes mellitus.

    abstract::Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验,评审

    doi:10.2165/00003495-200363160-00007

    authors: Dunn CJ,Plosker GL,Keating GM,McKeage K,Scott LJ

    更新日期:2003-01-01 00:00:00

  • Emerging options in the treatment of bipolar disorders.

    abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161100-00004

    authors: Berk M,Segal J,Janet L,Vorster M

    更新日期:2001-01-01 00:00:00

  • Abiraterone acetate: in metastatic castration-resistant prostate cancer.

    abstract::Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an e...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11208080-000000000-00000

    authors: Yang LP

    更新日期:2011-10-22 00:00:00

  • Nateglinide.

    abstract::Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (n...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060030-00007

    authors: Dunn CJ,Faulds D

    更新日期:2000-09-01 00:00:00

  • Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.

    abstract::A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700341-00017

    authors: Grassi C,Gialdroni Grassi G,Mangiarotti P

    更新日期:1987-01-01 00:00:00

  • Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.

    abstract::Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limite...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197510040-00001

    authors: Pinder RM,Brogden RN,Sawyer PR,Speight TM,Avery GS

    更新日期:1975-01-01 00:00:00

  • Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.

    abstract::Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue which, during continuous administration, down-regulates the pituitary-ovarian gonadal axis and reduces levels of the gonadotrophins, luteinising hormone and follicle-stimulating hormone. In women, this results in suppression of ovarian steroidogenesis and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651020-00009

    authors: Perry CM,Brogden RN

    更新日期:1996-02-01 00:00:00

  • Clinical aspects of invasive candidiasis in critically ill patients.

    abstract::Invasive candidiasis has emerged as an important cause of morbidity and mortality in intensive care unit patients. This short review focuses on many aspects of Candida infection in critically ill patients including epidemiology, impact on mortality, problems related to diagnosis, strategies to identify patients at ris...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11315590-000000000-00000

    authors: Pennisi M,Antonelli M

    更新日期:2009-01-01 00:00:00

  • [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

    abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856003-00004

    authors: Marquis P

    更新日期:1998-01-01 00:00:00

  • Clinical evidence with montelukast in the management of chronic childhood asthma.

    abstract:OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059001-00005

    authors: Becker A

    更新日期:2000-01-01 00:00:00

  • Management of Thrombotic Complications in COVID-19: An Update.

    abstract::Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01377-x

    authors: Hajra A,Mathai SV,Ball S,Bandyopadhyay D,Veyseh M,Chakraborty S,Lavie CJ,Aronow WS

    更新日期:2020-10-01 00:00:00

  • Quinidine and digoxin. An important interaction.

    abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00003

    authors: Bigger JT Jr,Leahey EB Jr

    更新日期:1982-09-01 00:00:00

  • Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

    abstract::Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565050-00007

    authors: Keam SJ,Croom KF,Keating GM

    更新日期:2005-01-01 00:00:00

  • Dual inhibitory action of nedocromil sodium on antigen-induced inflammation.

    abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198900371-00013

    authors: Dahlén SE,Björck T,Kumlin M,Sydbom A,Raud J,Palmertz U,Franzén L,Grönneberg R,Hedqvist P

    更新日期:1989-01-01 00:00:00

  • Emerging resistance to antimicrobial agents in gram-positive bacteria. Pneumococci.

    abstract::The prevalence of penicillin-resistant pneumococci is increasing worldwide. Methods for susceptibility testing, as well as in vitro susceptibility of penicillin-susceptible and -resistant strains to new and existing agents (including oral and parenteral streptogramins), are described. For all specimens except CSF, oxa...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600511-00003

    authors: Appelbaum PC

    更新日期:1996-01-01 00:00:00

  • Drug treatment of tropical parasitic infections: recent achievements and developments.

    abstract::Drug development offers potential solutions to a number of tropical health diseases, although the expense of pharmaceutical research and lack of return on investment has limited the production of new agents. The greatest successes have been through the development of single dose therapy and mass treatment control prog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060050-00002

    authors: Stephenson I,Wiselka M

    更新日期:2000-11-01 00:00:00

  • Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

    abstract::Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are cau...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0267-8

    authors: Viehman JA,Nguyen MH,Doi Y

    更新日期:2014-08-01 00:00:00

  • Studies with temocillin in the hamster model of antibiotic-associated colitis.

    abstract::The studies reported here were designed to ascertain whether or not the new beta-lactam antibiotic, temocillin, would produce antibiotic-associated colitis in the hamster. The experiments were controlled with clindamycin and cefoxitin, which are known to induce antibiotic-associated colitis experimentally and clinical...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00012

    authors: Boon RJ,Beale AS

    更新日期:1985-01-01 00:00:00

  • Inflammatory bowel disease management. Some thoughts on future drug developments.

    abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753020-00001

    authors: Rhodes J,Thomas G,Evans BK

    更新日期:1997-02-01 00:00:00

  • Drug-induced agranulocytosis.

    abstract::An unexpected precipitous fall in peripheral leucocyte count may occur during treatment of certain sensitised individuals with drugs usually well tolerated by most people. Three basic mechanisms for drug sensitivity have been found. One is characterised by sudden destruction of large numbers of leucocytes in periphera...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197815020-00003

    authors: Pisciotta V

    更新日期:1978-02-01 00:00:00

  • Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.

    abstract::Valsartan/hydrochlorothiazide is a fixed-dose (valsartan 80, 160 or 320mg plus hydrochlorothiazide 12.5 or 25mg) angiotensin II receptor blocker/diuretic drug combination indicated for the treatment of patients with essential hypertension not adequately controlled by monotherapy.There is ample evidence that valsartan/...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/00003495-200666140-00011

    authors: Wagstaff AJ

    更新日期:2006-01-01 00:00:00

  • Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

    abstract::Acamprosate (calcium acetylhomotaurinate), a synthetic compound with a similar chemical structure to that of gamma-aminobutyric acid, is thought to act via several mechanisms affecting multiple neurotransmitter systems; inhibition of neuronal hyperexcitability by antagonism of excitatory amino acid activity and reduct...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753060-00008

    authors: Wilde MI,Wagstaff AJ

    更新日期:1997-06-01 00:00:00

  • ZD1839 ('Iressa') as an anticancer agent.

    abstract::ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversib...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060001-00004

    authors: Baselga J,Averbuch SD

    更新日期:2000-01-01 00:00:00

  • Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

    abstract::Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11317050-000000000-00000

    authors: Pettengell R

    更新日期:2009-01-01 00:00:00

  • Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women.

    abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666170-00001

    authors: Mitwally MF,Casper RF

    更新日期:2006-01-01 00:00:00

  • Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.

    abstract:BACKGROUND:Generic drugs are approved on the basis of pharmaceutical equivalence and bioequivalence. Some drug products have unique structural or functional attributes, necessitating modified approaches to bioequivalence determinations. OBJECTIVE:The aim of this systematic review was to identify studies that evaluated...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0382-1

    authors: Kesselheim AS,Polinski JM,Fulchino LA,Isaman DL,Gagne JJ

    更新日期:2015-04-01 00:00:00

  • Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

    abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00046

    authors: Monassier JP,Hanssen M

    更新日期:1987-01-01 00:00:00